Levomilnacipran
- Generic Name
- Levomilnacipran
- Brand Names
- Fetzima
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22N2O
- CAS Number
- 96847-54-0
- Unique Ingredient Identifier
- UGM0326TXX
- Background
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran. Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in hum...
- Indication
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in adults.
- Associated Conditions
- Major Depressive Disorder (MDD)
- Associated Therapies
- -
Levomilnacipran in Healthy Males
- Conditions
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- University of Ottawa
- Target Recruit Count
- 36
- Registration Number
- NCT03249311
- Locations
- 🇨🇦
Institute of Mental Health Research, Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 60
- Registration Number
- NCT02720198
- Locations
- 🇺🇸
Institute for Advanced Medical Research, Alpharetta, Georgia, United States
Trial of Levomilnacipran in Geriatric Depression
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 29
- Registration Number
- NCT02466958
- Locations
- 🇺🇸
UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles, California, United States
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 552
- Registration Number
- NCT02431806
- Locations
- 🇺🇸
Innovative Clinical Research, Inc., Lauderhill, Florida, United States
🇺🇸Professional Psychiatric Services, Mason, Ohio, United States
🇺🇸Carilion Medical Center, Roanoke, Virginia, United States
Novel Medication as a Potential Smoking Cessation Aid
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 56
- Registration Number
- NCT02265367
- Locations
- 🇺🇸
Clinical and Translational Sciences Institute, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.